INS and myocardial infarction: A meta-analysis by Monami et al. (2008)[25] aimed to identify moderators of the effect of rosiglitazone on incidence of myocardial infarction and found that there was a significant correlation between the proportion of insulin-treated patients and rosiglitazone-associated risk of myocardial infarction (r = 0.42, p<0.05) (possibly related to the fact that both thiazolidinediones and insulin have an effect on fluid retention).